Literature DB >> 21494091

Intellectual property protection: strategies for antibody inventions.

Ulrich Storz1.   

Abstract

In the last decade, therapeutic antibodies have become one of the commercially most successful classes of biopharmaceutical drugs. Major drug manufacturers who have successfully managed to occupy this new market, as well as biotechnology firms, some of which have experienced a quick growth and are now on par with the former, owe part of their success to suitable intellectual property strategies. This article provides an overview of the current thinking on antibody-related patents, and discusses strategies for protecting the antibody products of the future.

Mesh:

Substances:

Year:  2011        PMID: 21494091      PMCID: PMC3149711          DOI: 10.4161/mabs.3.3.15530

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  5 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

Review 2.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 3.  Engineered protein scaffolds as next-generation antibody therapeutics.

Authors:  Michaela Gebauer; Arne Skerra
Journal:  Curr Opin Chem Biol       Date:  2009-06-06       Impact factor: 8.822

4.  Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1.

Authors:  Kevin W McCabe
Journal:  MAbs       Date:  2009-07-25       Impact factor: 5.857

5.  Toward biosimilar monoclonal antibodies.

Authors:  Christian K Schneider; Ulrich Kalinke
Journal:  Nat Biotechnol       Date:  2008-09       Impact factor: 54.908

  5 in total
  4 in total

1.  International intellectual property strategies for therapeutic antibodies.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 2.  The Cabilly patents: status quo and relevance for antibody companies.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

3.  Virtual screening for inhibitors of the human TSLP:TSLPR interaction.

Authors:  Dries Van Rompaey; Kenneth Verstraete; Frank Peelman; Savvas N Savvides; Koen Augustyns; Pieter Van Der Veken; Hans De Winter
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

4.  Addressing Barriers to the Development and Adoption of Rapid Diagnostic Tests in Global Health.

Authors:  Eric Miller; Hadley D Sikes
Journal:  Nanobiomedicine (Rij)       Date:  2015-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.